INKT (MiNK Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by INKT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-02 | Barbara Ryan | Director | A | — | — |
| 2026-09-02 | John Bradley Holcomb | Director | A | — | — |
| 2026-09-02 | Brian Corvese | Director | A | — | — |
| 2026-09-02 | ULF WIINBERG | Director | A | — | — |
| 2026-09-02 | Peter Behner | Director | A | — | — |
| 2026-06-05 | Barbara Ryan | Director | Sell | — | — |
| 2026-06-02 | John Bradley Holcomb | Director | A | — | — |
| 2026-06-02 | Barbara Ryan | Director | A | — | — |
| 2026-06-02 | Brian Corvese | Director | A | — | — |
| 2026-06-02 | ULF WIINBERG | Director | A | — | — |
| 2026-06-02 | Peter Behner | Director | A | — | — |
| 2026-03-11 | Barbara Ryan | Director | Sell | — | — |
| 2026-03-04 | Barbara Ryan | Director | Sell | — | — |
| 2026-01-14 | Jennifer Buell | Chief Executive Officer | F | — | — |
| 2026-01-06 | ULF WIINBERG | Director | A | — | — |
| 2026-01-06 | Peter Behner | Director | A | — | — |
| 2026-01-06 | Brian Corvese | Director | A | — | — |
| 2026-01-06 | Barbara Ryan | Director | A | — | — |
| 2026-01-06 | Jennifer Buell | Chief Executive Officer | A | — | — |
| 2025-12-03 | Robert Peter Kadlec | Director | A | — | — |
| 2025-12-03 | John Bradley Holcomb | Director | A | — | — |
| 2025-12-03 | ULF WIINBERG | Director | A | — | — |
| 2025-12-03 | Peter Behner | Director | A | — | — |
| 2025-12-03 | Brian Corvese | Director | A | — | — |
| 2025-12-03 | Barbara Ryan | Director | A | — | — |
| 2025-10-03 | Jennifer Buell | Chief Executive Officer | F | — | — |
| 2025-09-11 | ULF WIINBERG | Director | A | — | — |
| 2025-09-11 | Jennifer Buell | Chief Executive Officer | A | — | — |
| 2025-09-11 | Robert Peter Kadlec | Director | A | — | — |
| 2025-09-11 | Brian Corvese | Director | A | — | — |
| 2025-09-11 | Barbara Ryan | Director | A | — | — |
| 2025-09-11 | Peter Behner | Director | A | — | — |
| 2025-09-03 | Brian Corvese | Director | A | — | — |
| 2025-09-03 | Robert Peter Kadlec | Director | A | — | — |
| 2025-09-03 | Peter Behner | Director | A | — | — |
| 2025-09-03 | ULF WIINBERG | Director | A | — | — |
| 2025-09-03 | Barbara Ryan | Director | A | — | — |
| 2025-06-04 | Barbara Ryan | Director | A | — | — |
| 2025-06-04 | Robert Peter Kadlec | Director | A | — | — |
| 2025-06-04 | Brian Corvese | Director | A | — | — |
| 2025-06-04 | Peter Behner | Director | A | — | — |
| 2025-06-04 | ULF WIINBERG | Director | A | — | — |
| 2025-03-05 | Barbara Ryan | Director | A | — | — |
| 2025-03-05 | ULF WIINBERG | Director | A | — | — |
| 2025-03-05 | Brian Corvese | Director | A | — | — |
| 2025-03-05 | Peter Behner | Director | A | — | — |
| 2025-03-05 | Robert Peter Kadlec | Director | A | — | — |
| 2024-12-09 | Robert Peter Kadlec | Director | A | — | — |
| 2024-12-03 | Brian Corvese | Director | A | — | — |
| 2024-12-03 | ULF WIINBERG | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 2,175,306 | — |
| — | Director | 196,640 | — |
| — | Chief Executive Officer | 57,942 | — |
| — | Director | 54,770 | — |
| — | Director | 51,759 | — |
| — | Director | 24,404 | — |
| — | Director | 23,591 | — |
| — | Director | 19,126 | — |
| — | Director | 4,691 | — |
| — | Director | 4,119 | — |
| — | Chief Scientific Officer | 2,736 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the INKT quote page; the site-wide leaderboard is on the insider transactions hub.